 The Inverse Benefit Law states that the ratio of benefits to harms among patients taking new drugs tends to vary inversely with how extensively a drug is marketed. Two Americans, Howard Brody and Donald Light, have defined the Inverse Benefit Law, inspired by Tudor Hart's Inverse care law. A drug effective for a serious disorder is less and less effective as it is promoted for milder cases and for other conditions for which the drug was not approved. As effectiveness becomes more diluted, the risks of harmful side effects proliferate, thus the benefit-harm ratio worsens as a drug is marketed more widely. The inverse benefit law highlights the need for comparative effectiveness research and other reforms to improve evidence-based prescribing. The law is manifested through 6 basic marketing strategies: Many harms of new drugs are unexpected, and could be as serious as death. This is the reason why organizations like "Worst Pill, Best Pill" recommend not to use/prescribe new medications before being in the market for at least ten years (except in the very few cases of really important new drugs that solve previous unsolved problems). Agencies of drugs, committee of ethics and organizations of patients' safety should consider: 
